Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Tom, Thuren"'
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Autor:
Ulf Landmesser, Børge G Nordestgaard, Leslie Cho, Niels Eske Bruun, Sotirios Tsimikas, Stephen J Nicholls, A Michael Lincoff, Steven E Nissen, Eran Leitersdorf, Kathy Wolski, John Kastelein, Michael Blaha, Ryuichi Morishita, Junhao Liu, Brian Manning, Plamen Kozlovski, Anastasia Lesogor, Tom Thuren, Taro Shibasaki, Florin Matei, Fábio Serra Silveira, Andreas Meunch, Aysha Bada, Vinod Vijan
Publikováno v:
Open Heart, Vol 9, Iss 2 (2022)
Objective Lipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global
Externí odkaz:
https://doaj.org/article/69a4df2faa554bac9af4585ef3cef707
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Autor:
Steven E Nissen, Kathy Wolski, Leslie Cho, Stephen J Nicholls, John Kastelein, Eran Leitersdorf, Ulf Landmesser, Michael Blaha, A Michael Lincoff, Ryuichi Morishita, Sotirios Tsimikas, Junhao Liu, Brian Manning, Plamen Kozlovski, Anastasia Lesogor, Tom Thuren, Taro Shibasaki, Florin Matei, Fábio Serra Silveira, Andreas Meunch, Aysha Bada, Vinod Vijan, Niels Eske Bruun, Borge G Nordestgaard
Publikováno v:
Open heart, 9(2):002060. BMJ Publishing Group
Nissen, S E, Wolski, K, Cho, L, Nicholls, S J, Kastelein, J, Leitersdorf, E, Landmesser, U, Blaha, M, Lincoff, A M, Morishita, R, Tsimikas, S, Liu, J, Manning, B, Kozlovski, P, Lesogor, A, Thuren, T, Shibasaki, T, Matei, F, Silveira, F S, Meunch, A, Bada, A, Vijan, V, Bruun, N E & Nordestgaard, B G 2022, ' Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease ', Open Heart, vol. 9, no. 2, 002060 . https://doi.org/10.1136/openhrt-2022-002060
Nissen, S E, Wolski, K, Cho, L, Nicholls, S J, Kastelein, J, Leitersdorf, E, Landmesser, U, Blaha, M, Lincoff, A M, Morishita, R, Tsimikas, S, Liu, J, Manning, B, Kozlovski, P, Lesogor, A, Thuren, T, Shibasaki, T, Matei, F, Silveira, F S, Meunch, A, Bada, A, Vijan, V, Bruun, N E & Nordestgaard, B G 2022, ' Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease ', Open Heart, vol. 9, no. 2, 002060 . https://doi.org/10.1136/openhrt-2022-002060
ObjectiveLipoprotein(a) (Lp(a)) is an important genetically determined risk factor for atherosclerotic vascular disease (ASCVD). With the development of Lp(a)-lowering therapies, this study sought to characterise patterns of Lp(a) levels in a global
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6107b819850a91a166ab500d9942a4b
https://pubmed.ncbi.nlm.nih.gov/36384881
https://pubmed.ncbi.nlm.nih.gov/36384881
Autor:
Paul M. Ridker, Ronenn Roubenoff, Jens Praestgaard, Daniel H. Solomon, Linda Mindeholm, Herman Gram, Philip G. Conaghan, C. Scotti, Tom Thuren, Matthias Schieker
Publikováno v:
Ann Intern Med
Background: Osteoarthritis is a common inflammatory disorder with no disease-modifying therapies. Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear. Objective: To determine whether IL-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a3f28bb46c9fc60d35969a0f4ea9e3f
https://doi.org/10.7326/m20-0527
https://doi.org/10.7326/m20-0527
Autor:
Paul M. Ridker, Jan H. Cornel, Robert J. Glynn, Stefan D. Anker, Peter Libby, Brendan M. Everett, Mitja Lainscak, Antonio Abbate, Tom Thuren
Publikováno v:
Publons
Circulation, 139, 1289-1299
Circulation, 139, 10, pp. 1289-1299
Circulation, 139, 1289-1299
Circulation, 139, 10, pp. 1289-1299
Background: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d28c1406de32f9f7fea0649e15d4b117
https://hdl.handle.net/2066/215189
https://hdl.handle.net/2066/215189
Autor:
Jean G. MacFadyen, Tom Thuren, Peter Libby, Paul M. Ridker, Brendan M. Everett, Robert J. Glynn
Publikováno v:
Journal of the American College of Cardiology. 76(14)
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab significantly reduces the first major adverse cardiovascular event in patients with prior myocardial infarction (MI) and residual inflammatory risk (high-sensitivit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c93be470581fa296b342241e6eb433e
https://pubmed.ncbi.nlm.nih.gov/33004132
https://pubmed.ncbi.nlm.nih.gov/33004132
Autor:
Paul M. Ridker, Nancy Berliner, Peter Libby, Tom Thuren, Robert J. Glynn, Mounica Vallurupalli, Jean G. MacFadyen
Publikováno v:
Annals of internal medicine. 172(8)
Inflammatory cytokines, such as interleukin (IL)-1β, alter iron homeostasis and erythropoiesis, resulting in anemia, but whether inhibition of IL-1β can reverse these effects is unclear.To determine whether IL-1β inhibition with canakinumab reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002018290ddc560e0fb49af7c7ef4f7b
https://pubmed.ncbi.nlm.nih.gov/32658571
https://pubmed.ncbi.nlm.nih.gov/32658571
Autor:
Robert J. Glynn, Alexander M.K. Rothman, Peter Libby, Alastair J.S. Webb, Tom Thuren, David G. Harrison, Paul M. Ridker, Tomasz J. Guzik, Jean G. MacFadyen
While hypertension and inflammation are physiologically inter-related, the effect of therapies that specifically target inflammation on blood pressure is uncertain. The recent CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) afforded
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3834346164a5f6b63c3178c8de0900b5
https://ora.ox.ac.uk/objects/uuid:ed7a5495-d0c6-451e-a9e3-8781bad4ae1f
https://ora.ox.ac.uk/objects/uuid:ed7a5495-d0c6-451e-a9e3-8781bad4ae1f
Autor:
Wolfgang Koenig, Paul M. Ridker, Peter Libby, Brendan M. Everett, Robert J. Glynn, Jean G. MacFadyen, Hiroaki Shimokawa, Tom Thuren, Christie M. Ballantyne, Francisco Antonio Helfenstein Fonseca
Publikováno v:
European Heart Journal. 39:3499-3507
Aims Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent these beneficial cardiovascular outcomes are mediated through i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb90ca3f82f6f7ce8b5f71072ed846c
https://doi.org/10.1093/eurheartj/ehy310
https://doi.org/10.1093/eurheartj/ehy310
Autor:
Tom Thuren, Wolfgang Koenig, Paul M. Ridker, Brendan M. Everett, Peter Libby, Robert J. Glynn, Jean G. MacFadyen, Martin Lefkowitz, Jan H. Cornel
Publikováno v:
Journal of the American College of Cardiology. 71:2405-2414
Background Inflammation contributes to chronic kidney disease (CKD), in part mediated through activation of interleukin (IL)-1β by the NLRP3 inflammasome within the kidney. This process also likely contributes to the accelerated atherosclerosis asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf907143df7ad7f33ae5415e8b9e72cf
https://doi.org/10.1016/j.jacc.2018.03.490
https://doi.org/10.1016/j.jacc.2018.03.490
Publikováno v:
European Heart Journal. 40
Background The Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) established that targeting inflammation with interleukin-1b (IL-1b) inhibition can significantly reduce cardiovascular event rates in the absence of beneficial effects on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e554c0f47f6917be52748eaeb53bdb3
https://doi.org/10.1093/eurheartj/ehz748.0165
https://doi.org/10.1093/eurheartj/ehz748.0165